A geographic map of vaccine failure
Vaccination against infectious organisms has proven to be one of the most effective public health strategies for controlling and preventing disease. Vaccination strategies have shown specific benefit in low-and middle-income countries, where recent estimates suggest that by 2030 up to 36 million deaths will be averted simply by immunization against 10 common infections (1). Despite the dramatic successes predicted by models, accumulating evidence suggests that vaccine responses vary geographically and that efficacy rates, particularly for oral vaccines against polio, cholera, and rotavirus, are reduced in low-and middle-income countries (2) . For example, efficacy rates of Rotarixä, a vaccine against severe rotavirus-induced gastroenteritis, have been reported to be less than 50% for infants vaccinated in Malawi compared with their European counterparts (3) . Similarly, deficits in immunogenicity and/or efficacy have been documented for live-attenuated oral cholera vaccines (4) and for the trivalent oral poliovirus vaccine (TOPV), with up to a 30% reduction in seroconversion rates following administration in children in lowincome countries compared with children in industrialized countries (5) . It has even been suggested that the reduced OPV efficacy in low-income countries has contributed to the delayed global eradication of polio virus.
Interestingly, geographic variation in vaccine responsiveness is not limited to oral vaccines in infants but was described two decades ago for the Bacillus CalmetteGuerin (BCG) vaccine against mycobacterium tuberculosis (TB) (6) . BCG immunogenicity has been strongly linked to geographic latitude, with diminished efficacy closer to the equator (7). Similar geographic variation in vaccine immunogenicity was also observed for the yellow fever virus vaccine (YFV), with lower levels of neutralizing antibodies described in an adult Ugandan population compared with a control group in Switzerland (8) . Thus, similar geographic disparities have been observed in infants and adults, with both killed and live vaccines, vaccines directed at both bacterial and viral pathogens, and in parenteral and enteric delivery. Together, these discrepancies highlight the potential generalizability of the significant variation in immune responsiveness around the globe. However, while the overall trend of impaired immunogenicity in low-income countries appears to be common to multiple vaccine classes, the mechanism(s) responsible for this phenomenon remain unclear.
Genetics, nutrition, and the gut
A multitude of variables may be involved in shaping the responses to vaccination, with age, sexual phenotype, host genetic factors, environmental influences, nutritional status, and even the microbiome all having been suggested to affect vaccine responsiveness (9) (10) (11) . Variation in the HLA locus, which encodes the MHC proteins involved in antigen presentation, is among the top host genetic determinants linked to the heterogeneity of vaccine responses. Specific HLA class II alleles have been associated with both increased and reduced or nonresponse to the hepatitis B virus (HBV) vaccine as well as to other vaccines, including those for rubella and measles (12, 13) . Additionally, single nucleotide polymorphisms in cytokine and cytokine receptor genes have been shown to affect HBV, tetanus, and pneumococcal vaccine response rates (14) . Moreover, twin studies have proposed that genetic variation contributes to as much as 70% of the total observed variability for the HBV (15), measles (16) , and oral polio vaccines (17) .
In addition to genetic variables, poverty and associated malnourishment have been connected to limited or delayed acquisition of immunity, at least in children, following measles (18), tetanus, and diphtheria vaccination (19) . In addition to There is marked variability in vaccine efficacy among global populations. In particular, individuals in low-to middle-income countries have been shown to be less responsive to vaccines than those from developed nations. Several factors, including endemic infections, nutrition, genetics, and gut microbiome composition, have been proposed to underlie discrepancies in vaccine response. In this issue of the JCI, Kityo et al. evaluated response to yellow fever virus vaccine, inflammation, and lymphatic tissue architecture and fibrosis in three cohorts: two from the U.S. and one from Uganda. Compared with the U.S. subjects, the Ugandan cohort exhibited enhanced cytokine responses, increased lymph node fibrosis, reduced CD4 + T cell levels, and reduced vaccine response. Together, these results provide a link among chronic inflammation, damaged lymphoid architecture, and poor vaccine outcome, and set the stage for future studies to identify strategies to overcome these barriers. jci. (29) . Furthermore, there was a significant inverse correlation between TZ collagen deposition and TZ CD4 + T cell frequencies, known to be essential drivers of effective vaccine-induced antibody responses, suggesting T cell depletion in the Ugandans, even in the absence of HIV infection. To further determine if the observed differences in lymphatic tissue anatomy were associated with vaccine responsiveness, Kityo and colleagues (30) examined draining LNs 10-14 days after YFV and measured plasma YFV antibody titers by plaque reduction assay. Interestingly, not only was there a relative lack of primary follicles with fewer secondary follicles (germinal centers [GCs]) prior to vaccination in the Ugandan cohort, but also the majority of these individuals did not have a detectable increase in primary or secondary follicle formation following vaccination. Moreover, these immunological defects were consistent with a poor antibody response in the Ugandan cohort and correlated with increased damage in the fibroblastic reticular cell network (FRCn), an anatomic correlate of poor vaccine response. Thus, these data provide a definitive link among chronic inflammation, damaged lymphoid architecture, and poor vaccine outcome (Figure 1 ). adaptive immune responses (reviewed in ref. 28 ). Moreover, chronic infection and associated inflammation have been associated with altered lymphoid tissue architecture, particularly in HIV infection, and linked to T cell depletion (29) . However, the exact consequences of such changes in the context of vaccination have remained poorly understood, until now.
Structural effects on vaccineinduced immunity
In this issue, Kityo et al. (30) specifically explore the role of inflammation, tissue architecture, and fibrosis in modulating vaccine-induced immunity. In a tour de force, the study, which includes lymph node (LN) excisions and immune profiling, specifically aimed to define the linkage among LN inflammation, fibrosis, chronic immune activation, and vaccinedeficiencies in critical nutrients and the frequent occurrence of enteric dysfunction, the composition of the gut bacterial microbiota itself has been associated with vaccine immunogenicity (11) . Significant geographic differences have been linked to microbiome composition (20) , and recent data highlight similarities in microbiome composition in rotavirus vaccine responders in Ghana and the Netherlands compared with Ghanaian infant nonresponders (21) . Similarly, the specific presence of particular bacterial species in the stool microbiota of Bangladeshi infants, for example, has been associated with enhanced vaccine-specific IgG and T cell proliferative responses to the oral polio, BCG, tetanus toxoid, and HBV vaccines (22) . However, results implicating the microbiome in vaccine response variability have thus far been purely associative, and causal links to the microbiota, or information on how it may be exploited to improve immunity, have yet to emerge.
Coinfections: vaccine antagonists
Chronic exposure to and recurrent infections with intestinal helminths, Plasmodium, Mycobacterium, and other endemic pathogens affect more than a third of the global population, with a clear predominance in low-income countries where infection with at least one persistent pathogen is frequently found. Reduced responses to vaccinations for tetanus toxoid (23) , cholera (24) , and BCG (25) have been associated with helminth coinfection, and children with malaria have been shown to mount weaker antibody responses to tetanus toxoid, Haemophilus influenzae, meningococcal polysaccharide, and Salmonella typhi vaccination (26) than uninfected children. While some parasitic infections do not affect the initial generation or levels of protective antibody, parasitic infections clearly affect the durability of these immune responses, as reported for HBV or tetanus toxoid vaccines in chronic schistosomiasis (27) . Several mechanisms have been proposed for the antagonizing effects that coinfection has on vaccine durability. These include skewing of lymphocyte effector functions, induction of antiinflammatory cytokines, altered antigen presenting cell function, and reduced antigen processing and presentation, all of which result in poor or altered priming of 
